				DRUDPLIPED CALL TOOL
ORM P	TO-1390	0 (Modified) U.S. DEPARTMENT	FOR COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
			TO THE UNITED STATES	PP01521.101
		DESIGNATED/ELECTI	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR
	(CONCERNING A FILIN	NG UNDER 35 U.S.C. 371	□0.9
٠,	F	IONAL APPLICATION NO. PCT/US99/08802	INTERNATIONAL FILING DATE 22 April 1999	PRIORITY DATE CLAIMED 22 April 1998
		NVENTION		
ENH	ANC	ING IMMUNE RESPONSE	ES TO GENETIC IMMUNIZATION B	3Y USING A CHEMOKINE /
		Γ(S) FOR DO/EO/US		
Xavn	er ra	aliard /		1
4 nli	cont h	ith submits to the United St.	-to- Decimated/Planted Office (DO/PO/US)	d - C-11
			ates Designated/Elected Office (DO/EO/US) t	-
1.			items concerning a filing under 35 U.S.C. 371	
2.			QUENT submission of items concerning a fili	-
3.	\boxtimes	This is an express request to beg examination until the expiration	gin national examination procedures (35 U.S.) of the applicable time limit set in 35 U.S.C.	.C. 371(f)) at any time rather than delay 371(b) and PCT Articles 22 and 39(1).
4.	\boxtimes	-		he 19th month from the earliest claimed priority date.
[*] 5.	\boxtimes	A copy of the International App	olication as filed (35 U.S.C. 371 (c) (2))	
		a. is transmitted herewith	h (required only if not transmitted by the Inte	ernational Bureau).
			by the International Bureau.	
į		c. \square is not required, as the a	application was filed in the United States Rec	ceiving Office (RO/US).
6.		A translation of the Internationa	al Application into English (35 U.S.C. 371(c)))(2)).
7.	\boxtimes	A copy of the International Sear	rch Report (PCT/ISA/210).	
8.		Amendments to the claims of th	ne International Application under PCT Articl	le 19 (35 U.S.C. 371 (c)(3))
ļ :/		a. are transmitted herewit	ith (required only if not transmitted by the Inte	ternational Bureau).
ž.		b. \Box have been transmitted	by the International Bureau.	
oran professional		c. \square have not been made; he	nowever, the time limit for making such amen	ndments has NOT expired.
		d. have not been made an	nd will not be made.	
<u>.</u> 9.		A translation of the amendment	ts to the claims under PCT Article 19 (35 U.S.	S.C. 371(c)(3)).
10.	\boxtimes	An oath or declaration of the in-	ventor(s) (35 U.S.C. 371 (c)(4)).	
≒1 .		= =	liminary Examination Report (PCT/IPEA/409	·
]]		A translation of the annexes to t (35 U.S.C. 371 (c)(5)).	the International Preliminary Examination Re	eport under PCT Article 36
≕ It	ems 1	13 to 20 below concern documen	at(s) or information included:	
13.		An Information Disclosure Stat	tement under 37 CFR 1.97 and 1.98.	
14.	\boxtimes		ecording. A separate cover sheet in compliance	ce with 37 CFR 3.28 and 3.31 is included.
15.		A FIRST preliminary amendme		
16.		A SECOND or SUBSEQUENT	Γ preliminary amendment.	
17.		A substitute specification.		
18.		A change of power of attorney a		
19.	\boxtimes	Certificate of Mailing by Expres	ss Mail	
20.	\boxtimes	Other items or information:		
		Copy of Published Specification Written Opinion	ion with International Search Report	
		Witten Opinion		
ĺ				

U.S. A		NO. (IF KNOW)		INTERNATIONAL	APPLICAT	ION NO.		Ì	ATTOR	NEY'S	DOCKET	NUMBER
	<u>09</u>	Unknown 3	<u> 798 </u>	PCT/I	US99/0880	02				PP01	521.101	
21.		lowing fees are						CA	LCULA	TIONS	PTOL	JSE ONLY
			FR 1.492 (a) (1) -				1150	-				
	international	search fee (37	CFR 1.445(a)(2)	on fee (37 CFR 1.482) paid to USPTO I by the EPO or JPO.			c'd PC \$970.00	1/1	10	1 9	UCI	2000
×	International	preliminary ex	xamination fee (3)	7 CFR 1.482) not paid red by the EPO or JPC	d to		\$840.00					
	International	preliminary ex	xamination fee (3)	7 CFR 1.482) not paid (2)) paid to USPTO.	d to USPTO	1	\$690.00					
	International	preliminary ex	xamination fee nai	id to USPTO (37 CFR CT Article 33(1)-(4).	2 1 // 82)		\$670.00					
	International	preliminary ex	xamination fee pai	id to USPTO (37 CFR	2 1 /(22)		\$96.00					
				IATE BASIC FI		OUNT			\$1.8	10.00		
Surcha month:	rge of \$130.0 s from the ear	0 for furnishin liest claimed p	ng the oath or declar priority date (37 C	aration later than CFR 1.492 (e)).	□ 20	0 [30			\$0.00		
CL	AIMS	NUMI	BER FILED	NUMBER EX	TRA	RA	ATE					***
Total c		2	27 - 20 =	7		x \$1	8.00		\$12	26.00		
	ndent claims		2 - 3=	0		x \$7	78.00			\$0.00		
Multip	ole Dependent	t Claims (checl	k if applicable).	TARONE CAR	~~~~ ^ ~					\$0.00		
Daduct	tion of 1/2 for	- Gling hy ama		ABOVE CAL			=		\$1,93	36.00		
must a	lso be filed (1	Note 37 CFR 1	.9, 1.27, 1.28) (ch	able. Verified Small I heck if applicable).	Entity Stat	ement				\$0.00		
						TOTA	L =		\$1,93	36.00		
Proces months	sing fee of \$1.5 from the ear	30.00 for furni	ishing the English riority date (37 C	translation later than	□ 20	0 🗆	30 +					
		Transfer P.	tioney date (o. c	TOTAL NAT	PIONAI	מוקוקו ז		<u> </u>		\$0.00		
Fee for	recording the	e enclosed assi	compant (27 CED	1.21(h)). The assignm			\top		\$1,9.	36.00		
accomp	panied by an a	appropriate cov	ver sheet (37 CFR	3.28, 3.31) (check if	f applicabl	le).	×	<u> </u>		40.00		
4				TOTAL FEES	S ENCL	OSED) =	4 770.0		76.00		
1 17"11								Amo	unt to b refunded	e: d	\$	·
£1.0								<u> </u>	charged	1	\$	
		the amount of	ŕ	to cover the above								
		ge my Deposit	Account No. sheet is enclosed.	in the	amount of			to	cover th	ne abov	e fees.	
X	The Commi	ssioner is here	by authorized to c	charge any fees which	may he ree	quired o	- oradit aı	-11 OV6				
	to Deposit A			A duplicate copy of t				ly ove	грауше	nı		
NOTE	: Where an a	appropriate ti	ime limit under 3	37 CFR 1.494 or 1.49 ore the application to	5 has not l	haan ma		on to	revive (37 CFI	R	
		ESPONDENCE		te me appacation to	benums 2	tatus.		<u> </u>	2/	Λ		
	S. Dollard	SPUNDENCE	, TO:		٦		12/2	NI	had			
	S. Dollard ON CORPO	RATION				SIGNA	ATURE			<u></u>		
Intelle	ectual Proper				security of the security of th	Anne	S. Dolla	rđ				
	ox 8097 yville, Califo	rnia 94662-80	n 97			NAME						
US	,, -					43,93						
					DO SANCE		STRATIO	NI NII	NADED			
						4-			INTOTA			
							tober 20					
						DATE						

PCT/US99/08802

422 Rec'd PCT/PTO 1 9 OCT 2000

ENHANCING IMMUNE RESPONSES TO GENETIC IMMUNIZATION

This application claims the benefit of co-pending provisional application Serial No. 60/082,600 filed April 22, 1998, which is incorporated by reference herein.

TECHNICAL AREA OF THE INVENTION

The invention relates to the area of immune responses to genetic immunization. More particularly, the invention relates to enhancing immune responses to DNA immunogens using immune co-stimulatory molecules.

BACKGROUND OF THE INVENTION

The use of genetic immunization, or immunization with DNA encoding polypeptide immunogens, to prime immune responses is viewed as a promising vaccine strategy. This technology offers potential improvements compared to other types of vaccines, such as subunit proteins complexed with adjuvants or inactivated or attenuated viral preparations. In addition to the practical advantages of simplicity of construction and modification, injection of genetic material encoding for polypeptide immunogens results in synthesis of the immunogens in the host. Thus, these immunogens are presented to the host immune system with native post-translational modifications, structure, and conformation.

In mice, several DNA vaccines have been effective at inducing long-lived antibody and cytotoxic T lymphocyte (CTL) responses and have conferred protective immunity against a number of viruses, bacteria, parasites, and tumors (1-8). Various

15

البياة البياء البين يشتب من البياء ا

5

10

approaches to enhance immune responses mediated by genetic immunization have been investigated. In addition to variations in dosage, route or boosting regimens, these variations include co-injection of polynucleotides encoding co-stimulatory molecules which improve immunogen presentation to lymphocytes, such as B7-1 or B7-2, or cytokines, such as GM-CSF, IL-2, IL-2, and IL-12, to create an optimal cytokine microenvironment for T cell priming (11-19). However, further enhancement of immune responses to genetic immunization is desirable for immunizing mammals, particularly humans, against immunogens such as virus- and tumor-specific immunogens.

Thus, there is a need in the art for methods of enhancing the immune responses to DNA immunogens.

SUMMARY OF THE INVENTION

It is an object of the invention to provide a method of enhancing an immune response to a DNA immunogen. This and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention provides an immunogenic composition. The composition comprises a DNA immunogen and a chemokine or a polynucleotide encoding a chemokine.

Another embodiment of the invention provides a method of enhancing an immune response to a DNA immunogen in a mammal. A chemokine or a first polynucleotide encoding a chemokine and a DNA immunogen are administered to the mammal. An immune response to the DNA immunogen is thereby enhanced.

The present invention thus provides the art with the information that chemokines can be used to enhance an immune response of a mammal to a DNA immunogen. The invention can be used to, *inter alia*, to immunize or vaccinate a mammal against an infectious disease or a tumor.

.10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Figure 1 shows the immunization and bleeding schedules for animals immunized with HCV immunogens.

- Figure 2. Figure 2 shows the immunization and bleeding schedules for animals immunized with granulocyte-macrophage colony-stimulating factor (GM-CSF).
- Figure 3. Figure 3 shows the immunization and bleeding schedules for animals immunized with HCV immunogens and RANTES.
- Figure 4. Figure 4 shows the immunization and bleeding schedules for animals immunized with HCV immunogens and macrophage inflammatory protein 1α (MIP- 1α).
- Figure 5. Figure 5 shows the increased anti-HIV gag antibody titer in mice immunized with a plasmid encoding HIV gag and a plasmid encoding the chemokine B lymphocyte chemokine (BLC).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It is a discovery of the present invention that administration of a chemokine or a polynucleotide encoding a chemokine can be used to enhance an immune response in a mammal to a DNA immunogen. This method can be used, *inter alia*, to increase immunological resistance to pathogens, such as viruses and bacteria, and to tumor-associated immunogens.

Chemokines generally function as chemoattractants for cells which they recruit from the blood to sites of infection. Thus, administration of a chemokine, either together with or in addition to a DNA immunogen, effectively recruits various cell populations, including antigen presenting cells and effector cells, to the site of administration or its vicinity. Similarly, administration of a polynucleotide encoding a chemokine can result in local chemokine secretion which induces migration of antigen presenting cells and/or lymphocytes to the site of administration and which enhances immune responses to the DNA immunogen. Local chemokine secretion can also enhance the migration of cells which have taken up the DNA immunogen or

10

5

polypeptides encoded by the DNA immunogen to the lymph nodes, where priming of specific T cells can occur.

Chemokines which can be used in the method of the invention include, but are not limited to, B lymphocyte chemokine (BLC), IL-8, PBP/β-TG/NAP-2, macrophage inflammatory proteins MIP-1α, MIP-1β, and MIP-3α, macrophage chemoattractant and activating factor (MCP-1 or MCAF), MCP-2, MCP-3, I-309, C10, HCC-1, RANTES (regulated upon activation, normal T cell expressed and secreted), lymphotactin, SCM-1, eotaxin, MGSA, PF4, NAP-2, IP-10, ENA-78, EMF-1, GCP-2, SLC, ELC, and SDF-1. Certain chemokines may be more effective in combination with a particular DNA immunogen than others at stimulating an immune response; optimization of the DNA immunogen-chemokine combination can be carried out using routine assays in standard animal models (see Examples 1 and 2).

The immune response which is enhanced can be any response which is influenced by chemokines, including, but not limited to, antibody production or cytotoxic T lymphocyte (CTL) response resulting from chemoattraction and/or activation of antigen presenting cells, such as dendritic cells, macrophages, and monocytes, chemoattraction and/or activation of neutrophils, including eosinophils, and chemoattraction and/or activation of naive T cells, memory T cells, and pre-T cells to the thymus.

Measurement of enhanced immune responses can be carried out as is known in the art. For example, antibody titer can be measured by assays such as agglutination, immunoprecipitation, or ELISA.

Assays for chemotaxis relating to neutrophils are described in Walz et al. (1987), Biochem. Biophys. Res. Commun. 149: 755; Yoshimura et al. (1987), Proc. Natl. Acad. Sci. USA 84: 9233, and Schroder et al. (1987), J. Immunol. 139: 3474. Chemotaxis of lymphocytes can be assayed as described in Larsen et al., Science 243: 1464: (1989) and Carr et al., Proc. Natl. Acad. Sci. USA 91: 3652 (1994).

Assays for chemotaxis of tumor-infiltrating lymphocytes are described in Liao et al. (1995), J. Exp. Med. 182: 1301; for hemopoietic progenitors, in Aiuti et al. (1997), J. Exp. Med. 185: 111; for monocytes, in Valente et al. (1988), Biochem. 27:

4162; and for natural killer cells, in Loetscher et al. (1996), J. Immunol. 156: 322, and in Allavena et al. (1994), Eur. J. Immunol. 24: 3233.

Attraction or activation of eosinophils, dendritic cells, basophils, and neutrophils, can also be measured. Assays for determining eosinophil attraction are described in Dahinden et al., J. Exp. Med. 179: 751 (1994), Weber et al., J. Immunol. 154: 4166 (1995), and Noso et al., Biochem. Biophys. Res. Commun. 200: 1470 (1994). Attraction of dendritic cells can be measured as described, for example, in Sozzani et al., J. Immunol. 155: 3292 (1995). Assays for attracting basophils are taught in Dahinden et al., J. Exp. Med. 179: 751 (1994), Alam et al., J. Immunol. 152: 1298 (1994), and Alam et al., J. Exp. Med. 176: 781 (1992). Activation of neutrophils is taught in Maghazaci et al., Eur. J. Immunol. 26: 315 (1996) and Taub et al., J. Immunol. 155: 3877 (1995). Cytotoxic T lymphocyte assays can also be used to measure enhanced immune response to a DNA immunogen (see Example 1, below).

5

`10

The Hill Hall of the Committee of the Hill Hall of the Committee of the Co

The self-

20

25

30

The DNA immunogen can be any contiguous sequence of deoxyribonucleotides encoding a polypeptide which is capable of eliciting an immune response. For example, polynucleotides encoding immunogenic polypeptides of viruses such as HIV viruses (e.g., gag, pol, or env), herpes viruses (i.e., HSV-1, HSV-2), Epstein-Barr virus, varicella-zoster virus, cytomegalovirus, and hepatitis B virus (HBV), hepatitis C virus (HCV), and human papilloma viruses (i.e., HPV-16, -18, and -31) can serve as a DNA immunogen. DNA which encodes polypeptide immunogens of other infectious agents, such as bacteria, fungi, or yeast, can function as a DNA immunogen in the method of the invention. DNA which encodes polypeptides specifically expressed by a tumor, such as EGFRvIII, Ras, or p185^{HER2}, or polypeptides which are expressed both by a tumor and by the corresponding normal tissue, can also function as a DNA immunogen. If desired, a DNA immunogen can comprise coding sequences for more than one immunogenic polypeptide.

A chemokine and a DNA immunogen can be administered to a mammal, preferably a human, by any means known in the art, including parenteral, intranasal, or intramuscular injection, or coated onto small metal projectiles and injected using a biological ballistic gun ("gene gun"). Alternatively, a chemokine and a DNA immunogen can be administered successively. The chemokine can be administered

r. K.

prior to administration of the DNA immunogen, or the DNA immunogen can be administered prior to the administration of the chemokine.

A polynucleotide encoding the chemokine can also be administered. Preferably, a polynucleotide encoding the chemokine and a polynucleotide comprising the DNA immunogen are co-injected. The polynucleotides can also be administered successively, in any order. For co-administration, a single polynucleotide comprising both chemokine-encoding sequences and the DNA immunogen can be administered, or the DNA immunogen and the chemokine-encoding polynucleotide can be provided separately and mixed together prior to administration.

The invention also provides immunogenic compositions comprising a DNA immunogen and a chemokine or a polynucleotide encoding a chemokine. The composition can optionally comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those in the art. Such carriers include, but are not limited to, large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Pharmaceutically acceptable salts can also be used in compositions of the invention, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as feell as salts of organic acids such as acetates, proprionates, malonates, or benzoates. Compositions of the invention can also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents. Liposomes, such as those described in U.S. 5,422,120, WO 95/13796, WO 91/14445, or EP 524,968 B1, can also be used as a carrier for a composition of the invention.

Compositions of the invention can be used as vaccine compositions, for example, to enhance an immune response of a mammal, including a human, to an infectious agent or a tumor. The particular dosages of chemokine and DNA immunogen which are sufficient to enhance an immune response to the DNA immunogen will vary according to the chemokine and DNA immunogen being used and the mammal to which the chemokine and DNA immunogen are being administered. The amounts of each active agent in the examples described below provide general guidance for the range of each component to be utilized by the

- 10

10

5

WO 99/53960 PCT/US99/08802

practitioner upon optimizing the method of the present invention for practice either in vitro or in vivo. Generally, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, or 5 mg of a chemokine protein, a polynucleotide encoding a chemokine, or a polynucleotide comprising a DNA immunogen will be administered to a large mammal, such as a baboon or a human.

Such ranges by no means preclude use of a higher or lower amount of a component, as might be warranted in a particular application. For example, the actual dose and schedule may vary depending on whether the compositions are administered in combination with other pharmaceutical compositions or depending on individual differences in pharmacokinetics, drug disposition, and metabolism.

The following are provided for exemplification purposes only and are not intended to limit the scope of the invention described in broad terms above.

EXAMPLE 1

Co-administration of HCV immunogens and MIP-1 α increases lysis of autologous B cells infected with vaccinia virus encoding HCV polypeptide NS3

HCV immunogens. Each plasmid comprises a CMV enhancer/promoter and is Kanamycin-resistant. Plasmids were prepared by an alkaline lysis method from E. coli bacteria and purified using Qiagen purification systems. After purification, plasmids were stored at -80 °C, at a concentration of 1 mg/ml.

Plasmid pCMVKmΔNS comprises hepatitis C viral DNA encoding HCV polypeptides ΔNS3, NS4, NS5a, and NS5b (immunogen for animal Group 1). Plasmid NS-GM2 encodes HCV polypeptides ΔNS3, NS4, NS5b, NS5b, and hGM-CSF (immunogen for animal Group 2). Plasmid pCMVLhRantes encodes human RANTES protein. pCMVLhMIP1a encodes MIP-1α.

For the immunization protocols described below, pCMVKm\(Delta\)NS was premixed with either pCMVLhRantes (immunogen for animal Group 3) or pCMVLhMIP1a (immunogen for animal Group 4). Each plasmid was at a concentration of 1 mg/ml of DNA, for a total of 2 mg/ml of DNA per mixed

immunogen.

Injection of HCV immunogens into baboons. On the day of injection, one vial (marked with the plasmid name and animal group) per animal was removed from the freezer, thawed at room temperature, and gently mixed. Each immunogen was injected both intramuscularly and intradermally. The total volume injected per animal was 1 ml.

The left and right tibialis anterior muscle was injected with 400 µl of DNA for a total of 800 µl intramuscular injection per baboon, using a 1 ml syringe. The immunogens were injected slowly, over about 10 seconds. After injection, the needle was removed slowly, to reduce leakage.

Each of two separates sites of the upper back was injected with 100 µl of DNA for a total of 200 µl intradermal injection per baboon, using a 0.3 ml U-100 Insulin syringe. The skin at the sites of injection was shaved. At each site, the needle was inserted the needle bevel up into the skin and then rotated 90 degrees so that the bevel pointed to the side. The 100 µl was slowly injected over about 10 seconds. After injection, the needle was slowly rotated so that the bevel was up again, then withdrawn slowly to reduce leakage.

Immunization and bleeding schedules for four groups of baboons. Baboons in each of four groups were immunized and bled according to the following schedule. Group 1 (animals CK544, CK545, CK546, and CK547) received inoculations of pCMVKm ANS (HCV immunogens) and were bled according to the schedule in Group 2 (animals CK548, CK549, CK550, and CK551) received inoculations of NS-GM2 (HCV immunogens and GM-CSF) and were bled according to the schedule in Figure 2. Group 3 (animals CK552, CK553, CK554, and CK555) received inoculations of pCMVKm Δ NS and pCMVLhRantes (HCV immunogens and RANTES) according to the schedule in Figure 3. Group 4 (animals CK556, CK557, CK558, and CK559) received inoculations of pCMVKmANS and pCMVLhMIP1a (HCV immunogens and MIP-1α) and were bled according to the schedule in Figure 4.

Immunizations were carried out as described in Example 2, above. At each of the times indicated in the bleeding schedules, blood was drawn from the femoral vein

. 10

5

`10 .

Oral facts of the first the first that the first think of the first that the firs

25

while the baboons were under anesthesia (Ketamine®, 10 mg/ml). Blood was treated with heparin. B and T cells were isolated from these blood samples and used in the cytotoxic T lymphocyte assays described below.

CTL assays. Autologous B cell lines from each animal were established by transforming B cells with H. papio. Separate samples of peripheral blood mononuclear cells were restimulated with immortalized autologous B cells infected with a recombinant vaccinia virus that encodes each of the HCV immunogens (NS3, NS4, NS5a, and NS5b). Two weeks later, CD8⁺ T lymphocytes were purified from the samples using magnetic beads.

The ability of T cells from each animal to lyse its autologous B cell line infected with vaccinia virus encoding the same immunogens used to immunize the animals was tested using a standard ⁵¹Cr-release assay. Ratios of effector (T cells) to target (B cells) of 40:1, 10:1, and 2:1 were tested.

Percent lysis was calculated in each assay. A positive CTL response was noted if at least 10% more lysis occurred with homologous cells (stimulated with a vaccinia virus encoding an HCV immunogen) than with heterologous cells (stimulated with a vaccinia virus encoding an unrelated immunogen) for each of the two highest effector to target cell ratios tested.

Table I shows the number of animals with positive responses in a cytotoxic T lymphocyte assay.

Table I. Number of animals with CTL responses

Immunogen	No. of Animals
pCMVNS3-5	0/4
pCMVNS3-5 & MIP-1α	1/4
pCMVNS3-5 & RANTES	0/4

Table II shows percent lysis of target cells from animal CK556 after

10

He Hell He

25

PCT

restimulation. Homologous cells were stimulated with vaccinia virus encoding HCV polypeptide NS3.

Table II. Percent lysis of targets after restimulation (animal CK556)

	Effector:Target	Homologous ¹	Heterologous ²
pre-immunization	40:1	2	11
pre-immunization	10:1	6	10
pre-immunization	2:1	7	6
2 weeks post 3rd immunization	40:1	27	<1
2 weeks post 3rd immunization	. 10:1	17	<1
2 weeks post 3rd immunization	2:1	11	<1

The results reported in Table II demonstrate that co-administration of HCV immunogens and the chemokine MIP- 1α resulted in an increased lysis of autologous B cells infected with vaccinia virus encoding HCV polypeptide NS3.

EXAMPLE 2

Co-administration of HIV immunogens and BLC increases the titer of anti-p55gag

Balb/c mice received bilateral injections into the anterior tibialis muscle of 10 μg of a p55 plasmid, which encodes HIV gag, either alone or together with a total of 100 μg of a plasmid encoding B lymphocyte chemokine (BLC; *Nature 391*, 799-803, 1998). Fifty μg of BLC-encoding plasmid were injected into each muscle.

The animals were bled at 3 and 6 weeks after immunization, and anti-p55gag antibody titer was measured by ELISA. Figure 5 shows that anti-gag antibody titer in

¹ stimulated with a vaccinia virus encoding HCV polypeptide NS3.

² stimulated with a vaccinia virus encoding an unrelated immunogen.

WO 99/53960 PCT/US99/08802

immunized mice is increased at three weeks after immunization and continues to increase up to at least six weeks.

NUMBERED REFERENCES

- 1. Ulmer, J., et al. 1993. Heterologous protection against influenze by injection of DNA encoding a viral protein [see comments]. Science 259:1745-9.
- 2. Fynan, E., R. et al. 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. *Proc Natl Acad Sci USA* 90:11478-82.
- 3. Cox, G., et al. 1993. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 67:5664-7.
- 4. Sedegah, M., *et al.* 1994. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. *Proc Natl Acad Sci USA* 91:9866-70.
- 5. Barry, M., *et al.* 1995. Protection against mycoplasma infection using expression-library immunization. *Nature* 377-632-5.
- 6. Conry, R., et al. 1995. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 2:59-65.
- 7. Syrengelas, A., et al.. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038-1041
- 8. Tascon, R., et al. 1996. Vaccination against tuberculosis by DNA injection. Nat Med 2:888-92.
- 9. Yasutomi, Y., et al. 1996. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 70:678-81.
- 10. Letvin, M., et al. 1997. Potent protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. *Proc Natl Acad Sci USA* 94:9378-9383.
- 11. Xiang, Z., and H. Ertl. 1995. Manipulation of the immune responses to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. *Immunity* 2:129-35.
- 12. Conry, R., et al. 1996. Selected strategies to augment polynucleotide immunization. Gene Ther 3:67-74.

5

արդ կարդ կարդ արդ ուսար ուղղություն արդ կարդ կարդ կարդ արդ ուղղություն արդ ուղղություն արդ արդ արդ արդ արդ արդ

the this


. 120

30

5

- 13. Irvine, K., et al. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. *J. Immunol* 156:238-45.
- 14. Chow, Y., et al. 1997. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B Surface antigen and interleukin-2. J Virol 71:169-78.
- 15. Iwasaki, A., *et al.* 1997. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. *J Immmunol* 158:4591-601.
- 16. Kim, J., et al. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 158:816-26.
- 17. Okada, E., *et al.* 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. *J Immunol* 159:3638-47.
- 18. Geissler, M., et al. 1997. Enhancement of cellular and humoral immune responses to hepatitis C viruws core proteins using DNA-based vaccines augmented with cytokine-expressing plasmids. *J Immunol* 158:1231-7.
- 19. Larsen, D., et al. 1998. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. J Virol 72:1704-8.
- 20. Butcher, E. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell* 67:1033-6.
- 21. Springer, T. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 76:301-14.
- 22. Butcher, E., and L. Picker. 1996. Lymphocyte homing and homeostasis. *Science* 272:60-6.
- 23. Schall, T., and K. Bacon. 1994. Chemokines, leukocyte trafficking, and inflammation. *Curr Opin Immunol* 6:865-73.

- 10



- 25. Schall, T., *et al.* 1993. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. *J Exp Med* 177:1821-6.
- 26. Schall, T., et al. 1990. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. *Nature* 347:669-71.
- 27. Rot, A., et al. 1992. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 176:1489-95.

·10

We claim:

1. An immunogenic composition, comprising:

a DNA immunogen; and

- a chemokine or a polynucleotide encoding a chemokine.
- 2. The immunogenic composition of claim 1 wherein the DNA immunogen comprises a polynucleotide encoding a viral immunogen.
- 3. The immunogenic composition of claim 2 wherein the polynucleotide encodes a hepatitis C virus non-structural polypeptide.
- 4. The immunogenic composition of claim 3 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.
- 5. The immunogenic composition of claim 2 wherein the polynucleotide encodes an HIV polypeptide.
- 6. The immunogenic composition of claim 5 wherein the HIV polypeptide is a gag polypeptide.
- 7. The immunogenic composition of claim 1 wherein the DNA immunogen comprises a polynucleotide encoding an immunogen expressed by a tumor.
- 8. The immunogenic composition of claim 1 wherein the chemokine is macrophage inflammatory protein 1α (MIP- 1α).
- 9. The immunogenic composition of claim 1 wherein the chemokine is B lymphocyte chemokine (BLC).
- 10. The immunogenic composition of claim 1 further comprising a pharmaceutically acceptable carrier.
- 11. A method of enhancing an immune response to a DNA immunogen in a mammal, comprising the step of:

administering to the mammal (i) a chemokine or a first polynucleotide encoding a chemokine and (ii) a DNA immunogen, whereby an immune response to the DNA immunogen is enhanced.

12. The method of claim 11 wherein a chemokine is administered.

13. The method of claim 12 wherein the chemokine and the DNA immunogen are co-administered.

- 14. The method of claim 12 wherein the chemokine is administered prior to administration of the DNA immunogen.
- 15. The method of claim 12 wherein the DNA immunogen is administered prior to administration of the chemokine.
- 16. The method of claim 11 wherein a first polynucleotide encoding the chemokine is administered.
- 17. The method of claim 16 wherein the first polynucleotide and the DNA immunogen are co-administered.
- 18. The method of claim 16 wherein the polynucleotide is administered prior to administration of the DNA immunogen.
- 19. The method of claim 16 wherein the DNA immunogen is administered prior to administration of the first polynucleotide.
- 20. The method of claim 16 wherein a second polynucleotide which comprises(a) the first polynucleotide and (b) the DNA immunogen is administered.
- 21. The method of claim 11 wherein the chemokine is macrophage inflammatory protein 1α (MIP- 1α).
- 22. The method of claim 11 wherein the chemokine is B lymphocyte chemokine (BLC).
- 23. The method of claim 11 wherein the DNA immunogen comprises a polynucleotide which encodes a hepatitis C virus non-structural polypeptide.
- 24. The method of claim 23 wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.
- 25. The method of claim 23 wherein the polynucleotide encodes an HIV polypeptide.
- 26. The method of claim 25 wherein the HIV polypeptide is a gag polypeptide.
 - 27. The method of claim 11 wherein the mammal is a human.
- 28. The method of claim 11 wherein the immune response is an antibody response.

5

25

29. The method of claim 11 wherein the immune response is a cytotoxic T lymphocyte response.

. }

1 / 5

٠	
il.	il.
	en.
1	18
ř	ij
the state	ij.
-	Ą
ħ,	ilmit
ily, di	Ī
Ξ;	
	1
il Turbi	1
:r:Fee	2.34 2.34
÷	in in
15000	1
161131	THE STREET

							г																													
												טרים	rekion	13	2 0	5	0	0	-		- -	1	-	-	-	2 0	2 6	7 0	7	2	٣	3	2	999	666	900
		ー U L	5							% OF	MAX	REED	2					0#DIV/01						20 #DIV/01				20/ /00/	In/\n				20 #DIV/01			
		LI.	_							TOTAL	H.	IIME		(<u>m</u>	10		0	0	* 20	C	0	ρ	* 20	* 20	0	* 20	*			5	* 20	* 20	* 20	0	0	
								કંડકંડ		OTHER																										
	-	- -				·		CHIRON ????		HEPA-		מרמסם		BY (ml)		0	,	2	70	0	c	> 8	22	70	0	20	20	20	0	, 5	3 8	07	22			
Wt. ka						AVERAGE= #DIV/01		CHIRON		CLOTTED	פרתח	FOR	SERUM	(III)	0	0		> 0	٥	0	0	,)	0	0	0	0	0	0	C					0	0
SEX						4VERAGE=	01.50	SCHEDULE		CYCLE			į	IIME	ı	ı				0:0	4.0	C	200	0.0	#REFI	#REFI	#REFI	#REFI	#REFI	#BEE		FACT	#			
SFBR#	11117	11281	10070	11972	- 1		i	SSE					į	DLEEU#					Diepid O			ţ	-	7		P	4	ည		9	2	, 0	0	1		
CHIRON #	CX544	CX545	CVEAR	CX547						IMMUNOGEN					ı	ſ	-		21.14	PCMVK/MANS	pCMVKmANS PCMVKmANS			0147	pcmvkmans				pCMVKmANS							
													TAME	II MILLE	1	1	1			-	2			2	2				4					1	T	
									TOTAL	7		····	TIME/WKC)			,		-20		0.0	4.0	0.9	10.0	130	0.0	0.0	0.20	0.62	26.0	28.0	32.0	36.0	2 6		E E	ומטי
													DATE	NIA	UNI	NA	W	9/23/97	10/2/01	:]:	11/4/9/	11/18/97	12/18/97	1/8/08	1/20/08	9/17/08	2/11/30	06/11/6	4/1/98	4/21/98	5/19/98	6/16/98	LEE CONTRACTOR		TEN CENT	727
													STATUS					NEW																		

SUBSTITUTE SHEET (RULE 26)

14,000	IIII
1961	ī
÷	72
	<u>.</u>
	Min.
'n,	200
Hart.	17.3 Aud
æ	
	=in
Handt.	£
14	ď.
, ₁₈	ii.
11.12	27
No.	110

							_								,																				
	i	Λ	J								proton	LEKIOD	13			5	0	-	-	- -	-		-	2	2	2	1 0	7 2	ار	2	2	2	666	666	000
	(下にっ	5							WAX] 2 2					0 #DIV/01						20 #DIV/01				20 #PTV /01	2/27				20 #DIV/01			
		1	-						TOTAL	PER	TIME		(m)	0	2 0	2 0	0	* 20	C	0		* 20	* 20	0	* 20	* 20	100				× 20	* 20#	0	0	c
							3353		OTHER																							-			
						_	CHIRON CHIRON 2222		HEPA-	RINIZED	BLOUD		BY (ml)		c	, c	>	20	0	0	5	07	82	0	20	20	20	0	20	2 5	3 8	R7			
Wt. kg					#DIV/01	1	CHIRON		CLOTTED			SERUM	_1	0	0	-			0	0	C			0	0	0	0	0	0	c	0				0
SEX					AVERAGE=		BLEEDING	- -	CYCLE			ţ	I I ME	1	1			-	0:0	4.0	0	2 5	0.01	# #	AREI	#REFI	#REFI	#REFI	#REFI	#RED	IDCD.	#NELI	+	+	
SFBR#	11538	8854	9421	10645	1		BIE	ביי				יינייניים <i>ו</i> ו	םרבבח#					prebia o					7	¥	2	4	ဂ		9	7	α	5	1		
CHIRON #	CX548	CX549	CX550	CX551					IMMUNOGÉN					1	ı	1	1	NIC OHO	ZWO-CVI	NSGMZ			No Ollo	NO-CN				NS-GM2					-		
												TWW#		-	'	1	,	-	-	7			۲	2	1		1	4			-		+	\dagger	-
									TOTAL			TIME (WKS)	70	-			-2.0		2	4.0	6.0	10.0	130	0.00	10.0	020	20.0	79.0	78.0	32.0	38.0	P	E		22.
							·					DATE	NΑ	VIII	AN.	NA	9/25/97	10/9/01	7	18/0/11	11/20/97	12/18/97	1/8/98	1/22/98	2/10/08	3/10/08	96/61/5	4/9/98	96/07/4	17	6/18/98	OBL		180	T
												STATUS					NEW																		

SUBSTITUTE SHEET (RULE 26)

. - , W

FIG. 3

¥; SE SFBR# 9047 9801 10593 10399 CHIRON CX552 CX553 CX554 CX554 CX555

derty given, the signs given by given the signs of given or given with the strong that the strong that the strong that the signs of the signs with the signs of the sign of the s

								-	-								_						
			PERIOD	13	2 0		0	-	-	-	-	-	6	2 6	2	2	1 1) w	2	3	666	666	666
		% OF MAX	BLEED	!			0 #DIV/01					20 #DIV/01				20 #DIV/01				20 #DIV/01			
		TOTAL % OF PER MAX	TIME	(E	10	0	0	2	c	c	2	20#	0	20	12	202	o	28	2	20#	0	0	0
						-		*		-	*	*	_	*	*	*	_	*	*	*			
	غفف	OTHER																					
	CHIRON CHIRON ????	HEPA- RINIZED	BLOOD	BY (ml)		0	0	20	0	0	20	20	0	20	20	20	0	20	20	20			
AVERAGE= #DIV/01	CHIRON	CLOTTED BLOOD		SERUM (ml)	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NERAGE≕Į	BLEEDING SCHEDULE	CYCLE		"TIME"	1	ı	-	1	0.0	4.0	8.0	10.0	#REFI	#REFI	, #REFI	#REFI	#REFI	#REFI	#REFI	#REFI			
	BLEE			BLEED#				prebid 0			-	2		K	4	ಬ		9	7	8			
	_	IMMUNOGEN			1		-		pCMVKmANS+pCMVLhRanise	pCMVKmANS+pCMVLhRanise			pCMVKmANS+pCMVLhRanise	*			pCMVKmANS+pCMVLhRanise						
				IMM#	-	-	•	'		2			2				4						
		TOTAL		TIME(WKS) IMM#				-2.0	0.0	4.0	6.0			16.0	19.0	23.0	26.0	28.0	32.0	36.0	OB)	3	3
				DATE	NA	NA	NA	10/7/97	10/21/97	11/18/97	12/2/97	12/30/97	1/20/98	2/3/98	3/3/98	3/31/98	4/21/98	5/5/98	6/2/98	6/30/98	OB C	OB C	(BI)
				ATUS				*															


3/5

SUBSTITUTE SHEET (RULE 26)

4/5

	•	ct	•					PERIOD	13	2 0	c	0	,-	-	-	-	-		7	2	2	3	, ,) V.	2 6	000	666	666
	(F.G. 4	;				% OF MAX	BLEED VOL				0 #DIV/01	2 / 2 2				20 #DIV /01				20 #DIV/01				20 #DIV /01			
	į	Ĭ	•				TOTAL PER	TIME	(m)	0	0	Ö	20.2	0	C	20,0	207	0	2	20	707	0	20	20	20#	C	0	0
						-		····		-			*	-	-	*	*	-	#	*	*	-	*	*	*	L		
						نمنن	OTHER																					
						CHIRON CHIRON ????	HEPA- RINIZED	BLUUD	BY (ml)		0	0	22	0	0	20	20	0	20	20	20	0	20	20	20			
Wt. kg					#DIV/01	CHIRON	CLOTTED BLOOD	FOR		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SEX					AVERAGE= #DIV/01	BLEEDING SCHEDULE	LL.		"TIME"	1	l	ł	ı	0.0	4.0	0.9	10.0	#REFI	#REFI	#REFI	#REFI	#REFI	#REFI	#REFI	#REFI			
SFBR#	10850	6006	7750	10242		SCHI			BLEED#				prebld 0			-	2		ų	4	5		9	7	ω			
CHIRON #	CX556	CX557	CX558	CX559			IMMUNOGEN					_	•	pCMVkmANS+pCMVLhMIP1a	pCMVkmANS+pCMVLhMIP1a			pCMVkmANS+pCMVLhMIP1a				pCMVkmANS+pCMVLhMIP1a						
									IMM#	i			1		2		\neg	2				4						
							TOTAL		TIME(WKS) IMM#				-2.0	0.0	4.0	6.0	10.0	13.0	0.0	2.5	72.0	0.02	70.0	32.0	38.0	<u>B</u>	3	IBD
									DATE	AN S	AN S	AN	10/8/01	10/23/97	/6/07/11	12/4/9/	86/1/1	86/77/1	08/0/2	0/ 0/ 7	4/7/98	06/2/4	08///C	0/4/98	86/7//	OBI CALL	8 6	Ingi
								į	SOLATIONS	IST	ITO	WE!N	SH	EE	1 (1	RUL	E	26)										

The time of time of the time of time of the time of the time of the time of time o



Docket No. PP01521.101

Declaration For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

•	I believe I am the original, first and joint inventor (if p which a patent is sought or	lural names are listed	r (if only one name is listed belo d below) of the subject matter w d	w) or an original, which is claimed and for
•	ENHANCING IMMUNE RES	SPONSES TO GENETIC	CIMMUNIZATION BY USING A	CHEMOKINE
	the specification of which			
	(check one)			
i.	☐ is attached hereto.			
IJ .i	■ was filed on 22 April 1	999 -	as United States Application No	o. or PCT International
	Application Number P			
ij	and was amended on			
À			(if applicable)	
	I acknowledge the duty to known to me to be mate Section 1.56. I hereby claim foreign pri Section 365(b) of any foreign PCT International applications.	disclose to the Uniterial to patentability a ority benefits under gn application(s) for patentability and patentability	ed States Patent and Trademains defined in Title 37, Code of Title 35, United States Code, patent or inventor's certificate, of at least one country other the	rk Office all information f Federal Regulations, Section 119(a)-(d) or r Section 365(a) of any
	inventor's certificate or PC on which priority is claimed Prior Foreign Application(s	i international applic I.	checking the box, any foreign a ation having a filing date before	ipplication for patent or that of the application Priority Not Claimed
	N/A			
	(Number)	(Country)	(Day/Month/YearFiled)	
	(Number)	(Country)	(Day/Month/YearFiled)	
	(Number)	(Country)	(Day/Month/YearFiled)	

Form PTO-SB-01 (9-95) (Modified)

P02A/REV02

Patent and Trademark Office-U.S. DEPARTMENT OF

60/082600	22 April 1998	
(Application Serial No.)	(Filing Date)	_
(Application Serial No.)	(Filing Date)	_
(Application Serial No.)	(Filing Date)	_
PCT International application in the I acknowledge the duty to disclose known to me to be material to pate	ims of this application is no manner provided by the firs to the United States Patent entability as defined in Title	and Trademark Office all informates 37, CFR Section 1.56 which because 37.
PCT International application in the I acknowledge the duty to disclose known to me to be material to pate available between the filing date or date of this application:	ims of this application is no manner provided by the firs to the United States Patent entability as defined in Title	t disclosed in the prior United State t paragraph of 35 U.S.C. Section 1 and Trademark Office all informa 37, CFR Section 1.56 which beca
PCT International application in the I acknowledge the duty to disclose known to me to be material to pate available between the filing date or	ims of this application is no manner provided by the firs to the United States Patent entability as defined in Title	t disclosed in the prior United State t paragraph of 35 U.S.C. Section 1 and Trademark Office all informa 37, CFR Section 1.56 which beca
PCT International application in the I acknowledge the duty to disclose known to me to be material to pate available between the filing date or date of this application: N/A	ims of this application is no manner provided by the firs to the United States Patent entability as defined in Title f the prior application and t	t disclosed in the prior United State It paragraph of 35 U.S.C. Section 1 It and Trademark Office all informate In 37, CFR Section 1.56 which because the national or PCT International f

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Sole or first inventor's signature	Date October 200
Residence 148 SATURN ST, #1 SAN Citizenship USA	FRANCISCO, CA 94114 CA
Citizenship USA	
Post Office Address same as above	
Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of third inventor, if any	
Third inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	